Inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-beta) (IKK-beta)

Inhibitor of nuclear factor kappa-B kinase subunit beta (IKK-beta) is a central catalytic component of the IKK complex, which serves as the master regulator of the canonical NF-κB signaling pathway [1][2]. Upon stimulation by pro-inflammatory cytokines like TNF-α or IL-1, IKK-beta phosphorylates IκBα, leading to its proteasomal degradation and the subsequent nuclear translocation of NF-κB transcription factors [3]. This process activates genes essential for the immune response, cell survival, and inflammation [4]. In many diseases, including rheumatoid arthritis and various cancers, IKK-beta is overactive, contributing to chronic inflammation and tumor progression [5][6]. Consequently, IKK-beta is a high-priority therapeutic target, with several small-molecule inhibitors developed to block its kinase activity [7]. However, clinical development has been hindered by safety concerns, such as severe immunosuppression and potential hepatotoxicity, due to the target's fundamental role in normal cellular homeostasis [7][13].

Other names

IKK2IKKBNFKBIKBI-kappa-B kinase 2IKK-B

Drugs targeting this molecule typically act as ATP-competitive inhibitors of the IKK-beta kinase domain, preventing the phosphorylation of IκB proteins and thereby blocking the activation and nuclear translocation of NF-κB transcription factors [6][7].